Separately, JPMorgan Chase & Co. cut shares of Sienna Biopharmaceuticals from an overweight rating to a neutral rating in a research note on Monday, May 13th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Sienna Biopharmaceuticals presently has an average rating of Buy and an average price target of $21.67.
Shares of SNNA stock traded down $0.05 during mid-day trading on Thursday, reaching $0.83. 81,289 shares of the company’s stock traded hands, compared to its average volume of 260,464. Sienna Biopharmaceuticals has a 12 month low of $0.72 and a 12 month high of $18.05. The firm’s 50 day moving average price is $0.88. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.90. The stock has a market cap of $24.64 million, a price-to-earnings ratio of -0.23 and a beta of 2.90.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James & Associates bought a new position in Sienna Biopharmaceuticals in the 4th quarter worth about $54,000. Northern Trust Corp grew its stake in Sienna Biopharmaceuticals by 2.5% in the 4th quarter. Northern Trust Corp now owns 173,341 shares of the company’s stock worth $402,000 after acquiring an additional 4,230 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in Sienna Biopharmaceuticals in the 4th quarter worth about $36,000. Geode Capital Management LLC grew its stake in Sienna Biopharmaceuticals by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 168,219 shares of the company’s stock worth $390,000 after acquiring an additional 6,699 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in Sienna Biopharmaceuticals in the 4th quarter worth about $149,000. Institutional investors own 51.32% of the company’s stock.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.